What Could BSX Stock Be Worth In Three Years?

Boston Scientific (BSX) stock currently trades at 17.2 times earnings. This compares to an average multiple of 55.9 over the last twelve quarter-ends, excluding readings above a hundred. Investors evaluating the stock must look ahead to model potential returns. So what might a share bought at $43.31 be worth three years from now?

Three Years Out, Each Share Would Fetch About $47.80

Under this scenario, each share would gain 10.4% over three years, translating to about 3.3% a year. This model assumes sales grow 10.8% a year, capturing four-fifths of the 13.5% growth recorded in the twelve months through fiscal Q2 2026. That 13.5% pace was already slower than in either of the two prior years. The projection also assumes a lower P/E because sales grow more slowly than they did over the last twelve months.

Today and year three compare like this:

All of the projected gain comes from higher sales. Both the margin and the P/E decline in year three, and those two metrics alone would reduce the share value. Boston Scientific’s Cardiovascular segment made up 66% of its revenue in fiscal 2025. During fiscal Q2 2026, Cardiovascular sales grew 8%, while Interventional Cardiology within the segment grew 15%. Management expects Interventional Cardiology to be the company’s strongest growth driver.

What Does Management Expect For Boston Scientific’s Sales?

Management expects slower growth than the scenario assumes, making this projection the optimistic case. The company’s guidance of about 6.0% sales growth covers fiscal 2026 alone. The scenario applies a 10.8% rate over three years based on the pace of the last twelve months. On July 29, 2026, management lowered that guidance from an earlier guide of 7.75%. The reduction came from WATCHMAN, where the U.S. market slowed sharply, and from Electrophysiology, where competitors took more share than management expected.

Management stated that its other business units, which account for about 75% of revenue, should grow about 6% in the second half of 2026. The company expects these same pressures to keep revenue growth below market growth in 2027. Executives anticipate a meaningful improvement in 2028, when Boston Scientific plans seven new launches. For the scenario’s pace to hold, those launches would likely have to make up for two slower years.

What Could Lift Or Shrink Boston Scientific’s Upside?

The table below illustrates the impact of changing one assumption at a time while holding the other two constant:

This scenario begins with a high margin. Boston Scientific’s net margin of 17.5% over the last twelve months sits well above its 12.0% average from the prior twelve quarter-ends. The actual return per share would also be slightly lower than the scenario projects because the share count rose 1.3% over the last three years, whereas the model holds it flat.

Evaluating the variables individually reveals the break-even thresholds over a three-year holding period. Revenue growth could slow from 13.5% to 7.2% a year before the stock returns nothing. The net margin could fall from 17.5% today to 14.4% in year three before reaching that same zero-return line. Finally, the P/E could fall from 17.2 to 14.0.

Investors should closely watch the revenue growth figure for fiscal Q3 2026 in the earnings report expected on or around October 28, 2026.

Does This Mean You Should Act On BSX?

Our purpose is to inform you with unique data so you make the right investment decisions. That said, betting on a single stock is always risky, no matter which direction you choose.

There is a smarter approach. Since its inception, the Trefis High Quality (HQ) Portfolio has returned 105%, beating the benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. And it did so without taking the concentrated risk that comes with do-it-yourself stock picking. If that is how you want to invest, the HQ Portfolio is the place to start.